Citations

Showing 10 of 108162 citations.

The Balance between Open and Robotic Training among Graduating Urology Residents—Does Surgical Technique Need Monitoring?
Merrill, Suzanne B. , Sohl, Brian S., Thompson, R. Houston, Reese, Adam C. , Parekh, Dipen J. , Lynch, John H. , Grob, B. Mayer, Williams, Daniel H., Lee, Richard K. , Zaslau, Stanley , Guzzo, Thomas J., Shenot, Patrick J. , Lehman, Erik , Raman, Jay D.

Mayo Clinic

Journal of Urology | December 11, 2019 | Volume: 203 | Issue: 5 | Pages: 996-1002

10.1097/ju.0000000000000689 | PMID 31825298 Get It

Morning versus afternoon adenoma detection rate: a systematic review and meta-analysis
Barakat, Mohamed , Panchal, Ankur , Elhanafi, Sherif , Carr‐Locke, David L. , Othman, Mohamed O. , Abdelfatah, Mohamed M.

Mayo Clinic

European Journal of Gastroenterology & Hepatology | December 11, 2019 | Volume: 32 | Issue: 4 | Pages: 467-474

10.1097/meg.0000000000001596 | PMID 31834052 Get It

Adenoma detection rate (ADR) is a quality marker of colonoscopy and operator performance. Prior studies evaluating the effect of an extended workday on the ADR reported variable outcomes that remain controversial. Given the variable results of prior studies and the potential legal implications of reduced ADR in the afternoon, we aimed to further evaluate this parameter and its effect on ADR. We performed a systematic review of the PubMed, CINAHL and Scopus electronic databases. Studies were included if they reported ADR in patients undergoing colonoscopy in the morning session and the afternoon session. Afternoon sessions included both sessions following a morning shift and half-day block shifts. Subgroup analyses were performed for ADR comparing morning and afternoon colonoscopies in a continuous workday, advanced ADRs (AADRs) and polyp detection rates (PDRs) were also compared. Thirteen articles with 17 341 (61.2%) performed in the morning session and 10 994 (38.8%) performed in the afternoon session were included in this study. There was no statistical significance in the ADR or AADR between morning and afternoon sessions, respectively [relative risk (RR) 1.06, 95% confidence interval (CI) 0.99–1.14] and (RR 1.19, 95% CI 0.95–1.5). Afternoon procedures had a significantly higher PDR than morning procedures (RR 0.93, 95% CI 0.88–0.98). ADR was not significantly influenced in the afternoon session when operators continued to perform procedures throughout the day or on a half-day block schedule.
Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy
Marcath, Lauren A. , Vangipuram, Kiran, Gersch, Christina L. , Rae, James M. , Burness, Monika L. , Griggs, Jennifer J. , Poznak, Catherine Van , Hayes, Daniel F. , Henry, N. Lynn , Beutler, Andreas S. , Hertz, Daniel L. , Hertz, Daniel L , Henry, N Lynn , Kidwell, Kelley M. , Lavoie Smith, Ellen M

Mayo Clinic

British Journal of Clinical Pharmacology | December 11, 2019 | Volume: 86 | Issue: 5 | Pages: 880-890

10.1111/bcp.14192 | PMID 31823378 Get It

AimsChemotherapy‐induced peripheral neuropathy (PN) is a treatment limiting toxicity of paclitaxel. We evaluated if EPHA genetic variation (EPHA4, EPHA5, EPHA6, and EPHA8) is associated with PN sensitivity by accounting for variability in systemic paclitaxel exposure (time above threshold).MethodsGermline DNA from 60 patients with breast cancer was sequenced. PN was measured using the 8‐item sensory subscale (CIPN8) of the patient‐reported CIPN20. Associations for 3 genetic models were tested by incorporating genetics into previously published PN prediction models integrating measured paclitaxel exposure and cumulative treatment. Significant associations were then tested for association with PN‐related treatment disruption.ResultsEPHA5 rs7349683 (minor allele frequency = 0.32) was associated with increased PN sensitivity (β‐coefficient = 0.39, 95% confidence interval 0.11–0.67, p = 0.007). Setting a maximum tolerable threshold of CIPN8 = 30, optimal paclitaxel exposure target is shorter for rs7349683 homozygous (11.6 h) than heterozygous (12.6 h) or wild‐type (13.6 h) patients. Total number of missense variants (median = 0, range 0–2) was associated with decreased PN sensitivity (β‐coefficient: −0.42, 95% confidence interval −0.72 to −0.12, P = .006). No association with treatment disruption was detected for the total number of missense variants or rs7349683.ConclusionIsolating toxicity sensitivity by accounting for exposure is a novel approach, and rs7349683 represents a promising marker for PN sensitivity that may be used to individualize paclitaxel treatment.
Fragility Index in Cardiovascular Randomized Controlled Trials
Khan, Muhammad Shahzeb , Ochani, Rohan Kumar , Usman, Muhammad , Yamani, Naser, Murad, M. Hassan , Murad, M Hassan , Usman, Muhammad Shariq , Shaikh, Asim , Khan, Safi U. , Mandrola, John M , Doukky, Rami , Krasuski, Richard A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | December 11, 2019 | Volume: 12 | Issue: 12 | Pages: No page available

10.1161/circoutcomes.119.005755 | PMID 31822121 Get It

Background: Efficacy of an intervention is commonly evaluated using P values, in addition to effect size measures such as absolute risk reduction, relative risk reduction, and numbers needed to treat. However, these measures are not always intuitive to clinicians. The fragility index (FI) is a more intuitive number that can facilitate interpretation but can only be used with binary outcomes. FI is the minimum number of patients who must be moved from the nonevent group to the event group to turn a significant result nonsignificant. In this retrospective analysis, we assessed the robustness of cardiovascular randomized controlled trials (RCTs), which report a positive (statistically significant) primary outcome by using the FI. Methods and Results: We searched Medline from 2007 to 2017 to identify cardiovascular RCTs published in 6 high impact journals ( The Lancet , New England Journal of Medicine , Journal of the American Medical Association , Circulation , Journal of the American College of Cardiology and European Heart Journal ). Only RCTs with sample sizes >500 and a 2-by-2 factorial design or dichotomous primary outcomes were selected. FI was calculated using a defined approach. Among the cohort of 123 RCTs that met inclusion criteria, median FI was 13 (interquartile range, 5–26). In 28 trials (22.8%), FI ranged between 1 and 4. In 37 trials (30.1%), number of patients lost to follow-up was higher than the FI. Pharmaceutical interventions had higher FI compared with other interventions, FI=19 (7–52; P =0.002). Median FI varied according to subspecialty (electrophysiology=2; heart failure=11; interventional cardiology=8; P =0.020) and multiregional RCTs had higher FI=22 (12–53.25; P =0.023). FI did not differ based on risk of bias indicators, funding, or publication year. Conclusions: Considerable variations in FI were observed among cardiovascular trials, suggesting the need for careful interpretation of results, particularly when number of patients lost to follow-up exceeds FI.
Perioperative Spinal Cord Stimulation Management: A Clinical Scenario of Device Loss and Recommendations for Anesthesiologists
Hardman, Matthew I. , Hagedorn, Jonathan M.

Mayo Clinic

Pain Medicine | December 11, 2019 | Volume: 21 | Issue: 4 | Pages: 865-867

10.1093/pm/pnz352 | PMID 32040155 Get It

Proceedings from the 2018 Canadian Association for the Study of the Liver Single Topic Conference—Decompensated cirrhosis: from clinic to transplant
Dong, Victor , Gosselin, Maxime, Jagarlamudi, Nishita, Kok, Beverley, Swain, Mark G. , Bajaj, Jasmohan S. , Marquez, Vladimir , Stravitz, R. Todd , Merli, Manuela , Wong, Phil, Brisebois, Amanda, Wendon, Julia, Nyberg, Scott L. , Carrier, François Martin , Lucey, Michael R. , Rose, Christopher F. , Bissonnette, Julien , Gosselin, Maxime, Abraldeṣ, Juan G. , Montaño‐Loza, Aldo J. , Tandon, Puneeta , Wong, Florence , Feld, Jordan J. , Karvellas, Constantine

Mayo Clinic

Canadian Liver Journal | December 10, 2019 | Volume: 2 | Issue: 4 | Pages: 137-170

10.3138/canlivj.2019-0011 | PMID 35992765 Get It

Linkage Mapping for Foliar Necrosis of Soybean Sudden Death Syndrome
Chang, Hao‐Xun , Wen, Zixiang, Tan, Ruijuan, Dong, Hongxu , Wickland, Daniel P. , Wang, Dechun , Chilvers, Martin I.

Mayo Clinic

Phytopathology® | December 10, 2019 | Volume: 110 | Issue: 4 | Pages: 907-915

10.1094/phyto-09-19-0330-r | PMID 31821112 Get It

Sudden death syndrome (SDS) foliar symptoms consist of foliar chlorosis, foliar necrosis, leaf marginal curling, and premature defoliation, but resistance screening has been evaluated mostly based on the overall SDS foliar severity rather than on a specific foliar symptom. This study generated an F2 population derived from crossing the susceptible variety Sloan and the resistant germplasm line PI 243518, which exhibits resistance to both foliar chlorosis and necrosis. A total of 400 F2 lines were evaluated for foliar chlorosis, foliar necrosis, and overall SDS foliar symptoms, separately. Genotyping-by-sequencing was applied to obtain single nucleotide polymorphisms (SNPs) in the F2 population, and linkage mapping using 135 F2 lines with 969 high-quality SNPs identified a locus on chromosome 13 for foliar necrosis and SDS foliar symptoms. The locus partially overlaps with loci previously reported for SDS on chromosome 13, which is the third time the region from 15.98 to 21.00 Mbp has been reproduced independently and therefore qualifies this locus for a new nomenclature proposed as Rfv13-02. In summary, this study generated a new biparental population that enables not only the discovery of a locus for foliar necrosis and SDS foliar symptoms on chromosome 13 but also the potential for advanced exploration of SDS foliar resistance derived from the germplasm line PI 243518.
Pancreatic alpha-cell mass across adult human lifespan
Moin, Abu Saleh Md , Cory, Megan , Gurlo, Tatyana , Saisho, Yoshifumi , Rizza, Robert A., Butler, Peter C. , Butler, Alexandra E.

Mayo Clinic

European Journal of Endocrinology | December 10, 2019 | Volume: 182 | Issue: 2 | Pages: 219-231

10.1530/eje-19-0844 | PMID 31821160 Get It

Aim To establish pancreatic alpha-cell mass in lean, non-diabetic humans over the adult lifespan, performed as a follow-up study to beta-cell mass across the adult human lifespan. Methods We examined human pancreatic autopsy tissue from 66 lean, non-diabetic individuals aged from 30 to 102 years, grouped into deciles: 3rd (30–39 years), 4th (40–49 years), 5th (50–59 years), 6th (60–69 years), 7th (70–79 years), 8th (80–89 years) and 9th deciles (90+ years). Sections of pancreas were immunostained for glucagon and analyzed for fractional alpha-cell area. Population-based pancreatic volume data were used to calculate alpha-cell mass. Results With advanced age, the exocrine pancreas undergoes atrophy demonstrated by increased fat area (as % exocrine area) (0.05 ± 0.01 vs 1.6 ± 0.7% fat area of total exocrine pancreas, 3rd vs 9th decile, P < 0.05). Consequently, islet density increases with age (2.7 ± 0.4 vs 10.5 ± 3.3 islets/mm2, 3rd vs 9th decile, P < 0.05). Alpha-cell fractional area increases with advanced age (0.34 ± 0.05% vs 0.73 ± 0.26%, 3rd vs 9th decile, P < 0.05). However, alpha-cell mass remains constant at ~190 mg throughout the adult lifespan in lean, non-diabetic humans. Within islets, alpha-cell distribution between mantle and core is unchanged across deciles (1862 ± 220 vs 1945 ± 200 vs 1948 ± 139 alpha cells in islet mantle/mm2, 3rd vs 6th vs 9th decile, P = 0.93 and 1912 ± 442 vs 1449 ± 123 vs 1514 ± 168 alpha cells in islet core/mm2, 3rd vs 6th vs 9th decile, P = 0.47), suggesting that human islets retain their structural organization in the setting of age-related exocrine atrophy. Conclusions Consistent with our previous findings for beta-cell mass, alpha-cell mass remains constant in humans, even with advanced age. Pancreatic endocrine cells are much more robustly preserved than exocrine cells in aged humans, and islets maintain their structural integrity throughout life.
Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease
Tariq, Raseen , Disbrow, Molly, DiBaise, John K. , Orenstein, Robert , Saha, Srishti , Solanky, Dipesh , Loftus, Edward V. , Pardi, Darrell S. , Khanna, Sahil , Disbrow, Molly B, Loftus, Edward V , Tariq, Raseen

Mayo Clinic

Inflammatory Bowel Diseases | December 10, 2019 | Volume: 26 | Issue: 9 | Pages: 1415-1420

10.1093/ibd/izz299 | PMID 31821444 Get It

AbstractBackgroundClostridioides difficile infection (CDI) is associated with poor outcomes in inflammatory bowel disease (IBD) patients. Data are scarce on efficacy of fecal microbiota transplant (FMT) for recurrent CDI in IBD patients.MethodsWe reviewed health records of IBD patients (18 years of age or older) with recurrent CDI who underwent FMT. Outcomes of FMT for CDI were assessed on the basis of symptoms and stool test results.ResultsWe included 145 patients (75 women [51.7%]; median age, 46 years). Median IBD duration was 8 (range, 0–47) years, 36.6% had Crohn disease, 61.4% had ulcerative colitis, and 2.1% had indeterminate colitis. Median number of prior CDI episodes was 3 (range, 3–20), and 61.4% had received vancomycin taper. Diarrhea resolved after FMT in 48 patients (33.1%) without further testing. Ninety-five patients (65.5%) underwent CDI testing owing to post-FMT recurrent diarrhea; 29 (20.0%) had positive results. After FMT, 2 patients received empiric treatment of recurrent CDI without symptom resolution, suggesting IBD was the cause of symptoms. The overall cure rate of CDI after FMT was 80.0%, without CDI recurrence at median follow-up of 9.3 (range, 0.1–51) months. Forty-three patients (29.7%) had planned IBD therapy escalation after CDI resolution; none de-escalated or discontinued IBD therapy. Overall, 7.6% had worsening IBD symptoms after FMT that were treated as new IBD flares. No clinical predictors of FMT failure were identified.ConclusionsFew patients had new IBD flare after FMT. Fecal microbiota transplantation effectively treats recurrent CDI in IBD patients but has no apparent beneficial effect on the IBD course.
Incorporation of Telestroke into Neurology Residency Training: “Time Is Brain and Education”
Tipton, Philip W. , D’Souza, Caitlin E. , Greenway, Melanie R. F. , Peel, Jeffrey B. , Barrett, Kevin M. , Eidelman, Benjamin H., Mauricio, Elizabeth A. , Hattery, Wendy M., Siegel, Jason , Huang, Josephine F. , TerKonda, Sarvam P. , Siegel, Jason L, Tipton, Philip W , Meschia, James F. , Mauricio, Elizabeth A. , Demaerschalk, Bart M. , Freeman, William D.

Mayo Clinic

Telemedicine and e-Health | December 10, 2019 | Volume: 26 | Issue: 8 | Pages: 1035-1042

10.1089/tmj.2019.0184 | PMID 31821116 Get It

Background: With increasing demand for neurologists, nontraditional health care delivery mechanisms have been developed to leverage this limited resource. Introduction: Telemedicine has emerged as an effective digital solution. Over the past three decades, telemedicine use has steadily grown; however, neurologists often learn on the job, rather than as part of their medical training. The current literature regarding telestroke training during neurology training is sparse, focusing on cerebrovascular fellowship curricula. We sought to enhance telestroke training in our neurology residency by incorporating real-life application. Materials and Methods: We implemented a formal educational model for neurology residents to use telemedicine for remote acquisition of the National Institutes of Health Stroke Scale (NIHSS) for patients with suspected acute ischemic stroke (AIS) before arrival at our comprehensive stroke center. This three-phase educational model involved multidisciplinary classroom didactics, simulation exercises, and real-world experience. Training and feedback were provided by neurologists experienced in telemedicine. Results: All residents completed formal training in telemedicine prehospital NIHSS acquisition and had the opportunity to participate in additional simulation exercises. Currently, residents are gaining additional experience by performing prehospital NIHSS acquisition for patients in whom AIS is suspected. Our preliminary data indicate that resident video encounters average 10.6 min in duration, thus saving time once patients arrive at our hospital. Discussion: To our knowledge, this is the first report of a telestroke-integrated neurology residency program in a comprehensive stroke center resulting in shortened time to treatment in patients with suspected AIS. Conclusions: We present a model that can be adopted by other neurology residency programs as it provides real-world telemedicine training critical to future neurologists.